Related Experiment Videos

Gd-DTPA-enhanced MR imaging in mediastinal Hodgkin's disease

G Forsgren1, R Nyman, B Glimelius

  • 1Department of Diagnostic Radiology, University Hospital, Uppsala, Sweden.

Insights

Gadolinium-DTPA enhanced MRI effectively detects residual mediastinal Hodgkin's disease after treatment. Reduced signal intensity and contrast enhancement in MRI indicate inactive disease, aiding differentiation of necrotic or cystic lesions.

Area of Science:

  • Radiology
  • Oncology
  • Medical Imaging

Background:

  • Mediastinal Hodgkin's disease requires accurate assessment of treatment response.
  • Distinguishing residual active tumor from post-treatment changes is crucial.

Purpose of the Study:

  • To evaluate the role of Gd-DTPA enhanced MRI in assessing treatment response in primary mediastinal Hodgkin's disease.
  • To correlate MRI findings with treatment outcomes.

Main Methods:

  • 15 patients with primary mediastinal Hodgkin's disease underwent Gd-DTPA enhanced MRI before, during, and after treatment.
  • 43 MRI examinations were analyzed, focusing on signal intensity (SI) ratios in T2-weighted images and contrast enhancement.
  • Correlation between MRI parameters and treatment response was assessed.

Main Results:

  • After successful treatment, 13 patients showed residual masses with reduced T2-weighted SI ratio and decreased contrast enhancement.
  • A positive correlation was found between contrast enhancement, T2-weighted SI ratios, and tumor/residual mass characteristics.
  • Gd-DTPA enhanced MRI improved detection of necrotic/cystic lesions.
  • Low SI ratio and low contrast enhancement in residual masses suggested inactivity.

Conclusions:

  • Gd-DTPA enhanced MRI is valuable for evaluating treatment response in mediastinal Hodgkin's disease.
  • Reduced signal intensity and contrast enhancement on MRI can indicate inactive residual disease.
  • This technique aids in differentiating between solid, necrotic, and cystic lesions.

Related Concept Videos